Cell Transplantation (May 2008)

Riboflavin Inhibits IL-6 Expression and p38 Activation in Islet Cells

  • Lorenzo Cobianchi,
  • Alessia Fornoni,
  • Antonello Pileggi,
  • R. Damaris Molano,
  • Nahir Y. Sanabria,
  • Jorge Gonzalez-Quintana,
  • Nicola Bocca,
  • Simona Marzorati,
  • Elsie Zahr,
  • Anthony R. Hogan,
  • Camillo Ricordi,
  • Luca Inverardi M.D.

DOI
https://doi.org/10.3727/096368908785096060
Journal volume & issue
Vol. 17

Abstract

Read online

Riboflavin is a water-soluble vitamin that reduces the production of proinflammatory mediators and oxygen radicals. Because islet β-cells are very sensitive to oxidative stress and to cytokines, we investigated the possible cytoprotective effects of riboflavin on insulinoma NIT-1 cells and on isolated rodent islets. NIT-1 cells and islets cultured in the presence or absence of 10 μM riboflavin were studied at baseline and after exposure to cytokines (TNF-α, IL-1β, INF-γ). Riboflavin treatment did not affect islet cell viability as assessed by flow cytometry for caspases activation. However, riboflavin prevented the cytokine-induced increase in IL-6 mRNA expression and p38 phosphorylation analyzed by real-time PCR and immunoassay, respectively. In summary, nontoxic doses of riboflavin prevent cytokines-induced p38 phosphorylation and IL-6 upregulation in islet cells. This observation, together with the safety profile of riboflavin in the clinical setting, makes it an appealing agent for islet cytoprotection in islet transplantation protocols.